Michael Gendelman Email & Phone Number

Aug 2022 Exosome Diagnosticsto Present Account Manager Responsible for selling ExoDx a genomic urine test for risk assessment for high grade prostate cancer in men with an elevated PSA to, Urologists, Oncologists, in the medical office, acute care hospital, teaching institution urology departments and VA Hospital markets.• Exceeded Quota, 2023 • # 8 of 35 Reps, 2023• 117% year-over-year growth

Responsible for selling Gilotrif an oral TKI treatment for patients with EGFR metastatic non-small cell lung (NSCLC) cancer to Oncologists in the Medical Office. Teaching Institutions and VA Hospitals. Liaison with research vendor in collecting patient mutation data to assist in targeting customers effectively. Covered Central and Northeast Pennsylvania, Philadelphia, and South New Jersey.• Exceeded Quota, 2017, 2018, 2019 • Silver Award Winner, 2019

Responsible for selling PTEN / ERG FISH based tissue testing for post biopsy prostate cancer risk for aggressive disease to Urologists, Oncologist & Pathologists in Eastern Pennsylvania, New Jersey, Delaware, and Maryland. • Exceeded Quota, 2015• # 1 of 25 Reps, 2015• Company sold.

Responsible for selling CertNDx a genomic urine diagnostic test to detect bladder cancer. Call points include Urologists in the Physician Office and Acute Care Hospital Laboratories in Eastern Pennsylvania, South Jersey and Delaware.• Exceeded Quota, 2013 • # 5 of 25 Reps, Test Sales, 2012• Company lost reimbursement and closed

Responsible for selling Targis microwave-based capital equipment with disposable fibers that treat Benign Prosthetic Hyperplasia (BPH) or enlarged prostate to Urologists, Urologic Surgeons in the Physician Office market. • Exceeded Quota, 2007, 2008, 2009

Responsible for selling TUNA radiofrequency (RF) based capital equipment with disposable fibers that treat Benign Prosthetic Hyperplasia (BPH) or enlarged prostate to Urologists, Urologic Surgeons in the Physician Office and Ambulatory Surgery Center (ASC) markets. • Exceeded Quota, 2005• High Achiever Award, 2005• # 2 of 12 Reps, 2005

Eastern Pennsylvania And South Jersey

Responsible for selling the Indigo Laser system to treat Benign Prostatic Hyperplasia (BPH) or enlarged prostate including capital equipment and disposable laser fibers, as well as Trans Vaginal Tape (TVT) to treat women with urinary incontinence, and the Lifescan Hospital Based blood glucose monitoring system. Called on Urologists, Gynecologists, OB/Gyn’s, Urogynecologists, Radiation Oncologists, and Endocrinologists / Endocrinology in the Physician Office, Surgery, Operating Room, and… Show more Responsible for selling the Indigo Laser system to treat Benign Prostatic Hyperplasia (BPH) or enlarged prostate including capital equipment and disposable laser fibers, as well as Trans Vaginal Tape (TVT) to treat women with urinary incontinence, and the Lifescan Hospital Based blood glucose monitoring system. Called on Urologists, Gynecologists, OB/Gyn’s, Urogynecologists, Radiation Oncologists, and Endocrinologists / Endocrinology in the Physician Office, Surgery, Operating Room, and Outpatient Surgery markets. Counseled physicians on insurance and Medicare reimbursement.• Exceeded Quota, 1998, 1999, 2000, 2002 2003 YTD• Top Performer Award, Laser Fibers, 1999, 2000, 2001 Show less

Responsible for selling Lupron, a hormone injection used to treat prostate cancer, endometriosis, and uterine fibroids, as well as launching Prevacid, a proton pump inhibitor for acid reflux. Called on Urologists, Oncologists, Gynecologists and Gastroenterologists in Teaching Institutions VA Hospitals & Physician Offices.• Exceeded Quota, 1991, 1992, 1993, 1994, 1995, 1996, 1997 YTD

Bachelor Of Science, Exercise Science

Bachelor'S Degree, Exercise Physiology